Invokana 100mg Tablet contains Canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated for the management of type 2 diabetes mellitus. By inhibiting SGLT2 in the proximal renal tubules, Canagliflozin reduces glucose reabsorption and increases urinary glucose excretion, thereby lowering plasma glucose levels. This mechanism contributes to improved glycemic control when used as monotherapy or in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin. Invokana 100mg is typically prescribed for adult patients inadequately controlled on diet and exercise alone. Clinical studies have demonstrated its efficacy in reducing HbA1c, fasting plasma glucose, and postprandial glucose levels. Additionally, Canagliflozin has shown benefits in weight reduction and blood pressure lowering, which are advantageous in patients with metabolic syndrome. Common adverse effects include genital mycotic infections, urinary tract infections, increased urination, and potential volume depletion. Caution is advised in patients with renal impairment, as efficacy diminishes with decreased glomerular filtration rate, and dose adjustment or discontinuation may be necessary. Invokana is contraindicated in patients with type 1 diabetes or diabetic ketoacidosis. Regular monitoring of renal function and hydration status is recommended during therapy to ensure safety and optimize therapeutic outcomes.